Praxis Precision Medicines, Inc. (PRAX)
- Sector
- Biotechnology
- Last price
- $243.34
- As of
Kresmion compiles this page from PRAX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Praxis Precision Medicines, Inc. (PRAX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.
See the full PRAX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PRAX on one page. Preview it with sample data, then open it live with a free account.
Preview the PRAX dossierActive signals for PRAX
- highCONSENSUS_SELL
4 tracked funds reduced PRAX this 2026Q2, institutional consensus
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 23.1%, EPS $-2.87 vs $-3.7339 estimate
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 52% of PRAX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 85% of PRAX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 62% of PRAX (2026Q2)
FREE, NO ACCOUNT
Every signal on PRAX, as it fires
You are seeing 5 of 8 signals recorded on PRAX since 2026-05-17.
The five above landed across 3 days. The other 3 were recorded on 1 other days. 4 of the 8 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PRAX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 74006W207 · 2026Q2 | $6.3M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 74006W207 · 2026Q2 | $2.5M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 74006W207 · 2026Q2 | $1.7M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 74006W207 · 2026Q2 | $333K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PRAX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
PRAX against its peers
PRAX's return on equity of -34.5% ranks in the 48th percentile of 21 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.
| Metric | PRAX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 266M USD | 6 | 16 |
| Operating margin | n/a | -40.4% | n/a | 15 |
| Net margin | n/a | -40.4% | n/a | 15 |
| Return on equity | -34.5% | -22.3% | 48 | 21 |
| 1 year | 364.9% | 62.7% | 82 | 18 |
Peers (24): ALKS, IOVA, KOD, IONS, IMVT, CNTA, RYTM, GRAL, BLTE, LGND, ABVX, SYRE, ARWR, CAI, CGON, TGTX, ERAS, MIRM, MANE, ORKA, PTCT, CYTK, COGT, CRNX. Left out: BCHMY (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (PRAX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow PRAX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to PRAX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.